8-(diethylaminomethyl)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-hydroxy-1-benzopyran-4-one : no description available [CHeBI]
| ID Source | ID |
|---|---|
| PubMed CID | 5503040 |
| CHEMBL ID | 1430886 |
| CHEBI ID | 115694 |
| Synonym |
|---|
| AKOS002181270 |
| smr000145831 |
| 8-diethylaminomethyl-3-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-7-hydroxy-chromen-4-one |
| MLS000552107 , |
| CHEBI:115694 |
| 8-(diethylaminomethyl)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-hydroxychromen-4-one |
| STK923047 |
| HMS2181A08 |
| F3139-1769 |
| 637751-78-1 |
| 8-((diethylamino)methyl)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-7-hydroxy-4h-chromen-4-one |
| CHEMBL1430886 |
| 8-(diethylaminomethyl)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-hydroxy-chromone |
| 8-(diethylaminomethyl)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-hydroxy-1-benzopyran-4-one |
| cid_5503040 |
| 8-(diethylaminomethyl)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-oxidanyl-chromen-4-one |
| bdbm68774 |
| Q27198044 |
| Class | Description |
|---|---|
| isoflavones | Any isoflavonoid with a 3-aryl-1-benzopyran-4-one (3-aryl-4H-chromen-4-one) skeleton and its substituted derivatives. |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 31.6228 | AID2147 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 50.1187 | AID485281 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 25.1189 | AID504937 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 56.2341 | AID588456 |
| ClpP | Bacillus subtilis | Potency | 28.1838 | AID651965 |
| TDP1 protein | Homo sapiens (human) | Potency | 6.7934 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 31.6228 | AID1460 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 28.1838 | AID1030 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 31.6228 | AID894 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 11.2202 | AID1688 |
| geminin | Homo sapiens (human) | Potency | 29.0929 | AID624296 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 22.3872 | AID1487 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 11.2202 | AID624287 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| glycogen synthase kinase-3 beta isoform 1 | Homo sapiens (human) | EC50 | 300.0000 | AID434954 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 ISSN: 1945-7170 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X | |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 ISSN: 1945-7170 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X | |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 ISSN: 1552-454X | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2022 | Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 37, Issue:1 ISSN: 1475-6374 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ipriflavone | aromatic ether; isoflavones | bone density conservation agent | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | ||
| isoflavone | isoflavones | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 7-Acetoxy-2-methylisoflavone | isoflavones | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | |||
| acetic acid (4-oxo-3-phenyl-1-benzopyran-7-yl) ester | isoflavones | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 4-methyl-2-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]pentanoic acid [3-(4-nitrophenyl)-4-oxo-1-benzopyran-7-yl] ester | isoflavones | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 7-hydroxy-8-(4-morpholinylmethyl)-3-phenyl-1-benzopyran-4-one | isoflavones | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | |||
| lupiwighteone | isoflavones | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 7-Hydroxy-2-methylisoflavone | isoflavones | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 3-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-5,7-dihydroxy-2-methyl-1-benzopyran-4-one | isoflavones | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 4',7,8-trihydroxyisoflavone | isoflavones | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inflammation | 0 | 2010 | 2010 | 14.0 | high | 0 | 0 | 0 | 1 | 0 | 0 | |
| Innate Inflammatory Response | 0 | 2010 | 2010 | 14.0 | high | 0 | 0 | 0 | 1 | 0 | 0 | |
| Malaria, Falciparum | 0 | 2014 | 2014 | 10.0 | high | 0 | 0 | 0 | 0 | 1 | 0 | |
| Plasmodium falciparum Malaria | 0 | 2014 | 2014 | 10.0 | high | 0 | 0 | 0 | 0 | 1 | 0 |